150 related articles for article (PubMed ID: 23392775)
1. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.
Dings RP; Levine JI; Brown SG; Astorgues-Xerri L; MacDonald JR; Hoye TR; Raymond E; Mayo KH
Invest New Drugs; 2013 Oct; 31(5):1142-50. PubMed ID: 23392775
[TBL] [Abstract][Full Text] [Related]
2. Targeting the CRD F-face of Human Galectin-3 and Allosterically Modulating Glycan Binding by Angiostatic PTX008 and a Structurally Optimized Derivative.
Miller MC; Zheng Y; Suylen D; Ippel H; Cañada FJ; Berbís MA; Jiménez-Barbero J; Tai G; Gabius HJ; Mayo KH
ChemMedChem; 2021 Feb; 16(4):713-723. PubMed ID: 33156953
[TBL] [Abstract][Full Text] [Related]
3. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities.
Dings RP; Chen X; Hellebrekers DM; van Eijk LI; Zhang Y; Hoye TR; Griffioen AW; Mayo KH
J Natl Cancer Inst; 2006 Jul; 98(13):932-6. PubMed ID: 16818857
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of calix[4]arene-based carbonyl amide derivatives with antitumor activities.
An L; Wang C; Zheng YG; Liu JD; Huang TH
Eur J Med Chem; 2021 Jan; 210():112984. PubMed ID: 33183867
[TBL] [Abstract][Full Text] [Related]
5. Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation.
Läppchen T; Dings RP; Rossin R; Simon JF; Visser TJ; Bakker M; Walhe P; van Mourik T; Donato K; van Beijnum JR; Griffioen AW; Lub J; Robillard MS; Mayo KH; Grüll H
Eur J Med Chem; 2015 Jan; 89():279-95. PubMed ID: 25462244
[TBL] [Abstract][Full Text] [Related]
6. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.
Dings RP; Miller MC; Nesmelova I; Astorgues-Xerri L; Kumar N; Serova M; Chen X; Raymond E; Hoye TR; Mayo KH
J Med Chem; 2012 Jun; 55(11):5121-9. PubMed ID: 22575017
[TBL] [Abstract][Full Text] [Related]
7. Ilexgenin A induces B16-F10 melanoma cell G1/S arrest in vitro and reduces tumor growth in vivo.
Yang H; Liu C; Zhang YQ; Ge LT; Chen J; Jia XQ; Gu RX; Sun Y; Sun WD
Int Immunopharmacol; 2015 Feb; 24(2):423-431. PubMed ID: 25596038
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Anticancer Activities of Novel Facile Synthesized Calix[n]arene Sulfonamide Analogs.
Yilmaz B; Bayrac AT; Bayrakci M
Appl Biochem Biotechnol; 2020 Apr; 190(4):1484-1497. PubMed ID: 31782087
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, X-ray crystal structure and anti-tumor activity of calix[n]arene polyhydroxyamine derivatives.
An L; Han LL; Zheng YG; Peng XN; Xue YS; Gu XK; Sun J; Yan CG
Eur J Med Chem; 2016 Nov; 123():21-30. PubMed ID: 27474920
[TBL] [Abstract][Full Text] [Related]
10. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
[TBL] [Abstract][Full Text] [Related]
11. Improved delivery of doxorubicin using rationally designed PEGylated platinum nanoparticles for the treatment of melanoma.
Mukherjee S; Kotcherlakota R; Haque S; Bhattacharya D; Kumar JM; Chakravarty S; Patra CR
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110375. PubMed ID: 31924026
[TBL] [Abstract][Full Text] [Related]
12. Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells.
Ren PT; Zhang Y
Mol Med Rep; 2017 Apr; 15(4):1533-1538. PubMed ID: 28260039
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells.
Kim KN; Ahn G; Heo SJ; Kang SM; Kang MC; Yang HM; Kim D; Roh SW; Kim SK; Jeon BT; Park PJ; Jung WK; Jeon YJ
Environ Toxicol Pharmacol; 2013 Jan; 35(1):39-46. PubMed ID: 23228706
[TBL] [Abstract][Full Text] [Related]
14. Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy.
Pelizzaro-Rocha KJ; de Jesus MB; Ruela-de-Sousa RR; Nakamura CV; Reis FS; de Fátima A; Ferreira-Halder CV
Biochim Biophys Acta; 2013 Dec; 1833(12):2856-2865. PubMed ID: 23872419
[TBL] [Abstract][Full Text] [Related]
15. Antitumoural effect of Synadenium grantii Hook f. (Euphorbiaceae) latex.
de Oliveira TL; Munhoz AC; Lemes BM; Minozzo BR; Nepel A; Barison A; Fávero GM; Campagnoli EB; Beltrame FL
J Ethnopharmacol; 2013 Oct; 150(1):263-9. PubMed ID: 24008110
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo anticancer effects of Lithospermum erythrorhizon extract on B16F10 murine melanoma.
Rajasekar S; Park DJ; Park C; Park S; Park YH; Kim ST; Choi YH; Choi YW
J Ethnopharmacol; 2012 Nov; 144(2):335-45. PubMed ID: 22995444
[TBL] [Abstract][Full Text] [Related]
17. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Rabinovich GA; Bieche I; Vidaud M; de Gramont A; Martinet M; Cvitkovic E; Faivre S; Raymond E
Eur J Cancer; 2014 Sep; 50(14):2463-77. PubMed ID: 25042151
[TBL] [Abstract][Full Text] [Related]
18. Anti-proliferative and cytotoxic activity of pentadactylin isolated from Leptodactylus labyrinthicus on melanoma cells.
Libério MS; Joanitti GA; Azevedo RB; Cilli EM; Zanotta LC; Nascimento AC; Sousa MV; Pires Júnior OR; Fontes W; Castro MS
Amino Acids; 2011 Jan; 40(1):51-9. PubMed ID: 20012549
[TBL] [Abstract][Full Text] [Related]
19. Mastoparan induces apoptosis in B16F10-Nex2 melanoma cells via the intrinsic mitochondrial pathway and displays antitumor activity in vivo.
de Azevedo RA; Figueiredo CR; Ferreira AK; Matsuo AL; Massaoka MH; Girola N; Auada AV; Farias CF; Pasqualoto KF; Rodrigues CP; Barbuto JA; Levy D; Bydlowski SP; de Sá-Junior PL; Travassos LR; Lebrun I
Peptides; 2015 Jun; 68():113-9. PubMed ID: 25305549
[TBL] [Abstract][Full Text] [Related]
20. A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.
Liang Y; Li S; Wang X; He B; He B; Dai W; Zhang H; Wang X; Wang Y; Zhou D; Zhang Q
Theranostics; 2017; 7(13):3306-3318. PubMed ID: 28900511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
